Mylan, Approval of Copaxone Should Provide an Accretive Boost, G - Erie News Now | WICU & WSEE in Erie, PA

Mylan, Approval of Copaxone Should Provide an Accretive Boost, Generic Advair Next?

Posted: Updated:

NEW YORK, NY / ACCESSWIRE / October 5, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Mylan N.V. (NASDAQ: MYL), a global pharmaceutical company. The company develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products. Mylan is known for its strength in the generic pharmaceutical industry. Overall, the company’s product portfolio consists of more than 7,500 marketed products sold in 165 countries and territories.

On October 4, the FDA approved Mylan’s generic version of Copaxone (Glatiramer Acetate Injection), a multiple sclerosis (MS) drug made by Israel’s Teva Pharmaceutical. Copaxone is the most prescribed MS treatment in the United States with brand sales of $700 million for the 20mg dose and $3.6 billion for the 40mg dose. The company received approval for both 20mg and 40mg doses of the drug, and may be eligible for 180 days of exclusivity.

Read about the specific accretive value of Copaxone and get a MYL market overview READ MORE

Copy and paste to your browser may be required to view the report –

The recent approval of generic Copaxone was prompted by the FDA announcing that it would be introducing measures to approve generic versions of complex drugs more quickly to combat rising drug prices. While this could affect sales of Mylan’s own branded EpiPen, the company will benefit from more expeditious approvals of other generic products. In addition to generic Copaxone, the company is hoping to launch a generic version of GlaxoSmithKline’s Advair asthma treatment.

See what the analysts say about MYL, a financial review and company guidance here READ MORE

Copy and paste to your browser may be required to view the report –


Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the ”Author”) and is fact checked and reviewed by a third-party research service company (the ”Reviewer”) represented by a chartered financial analyst, for further information on analyst credentials, please email Ivan Neilson, a CFA® charter holder (the ”Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer be featured on our coverage list, contact us via email at:

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE: Traders News Source

ReleaseID: 477099

Information contained on this page is provided by an independent third-party content provider. Frankly and this Station make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact

Powered by Frankly
3514 State St. Erie, PA 16508
Newsroom: (814) 454-8812
Business offices: (814) 454-5201
Share Stories
Submit your stories to our site!
Share Photos
Share your photos in our community galleries
RSS Feeds
All content © Copyright 2000 - 2017 WICU. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.
                   WICU/WSEE - 3514 State Street Erie, PA 16508 - (814) 454-5201 -